Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2023-10-25 Capital/Financing Update
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
News release - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing new orders potentially totaling over 2.6 million Canadian dollars annually for Groupe LSL Pharma. It discusses business developments, sales growth, and strategic plans but does not contain any financial statements, detailed financial results, or regulatory filings. There is no indication of quarterly or annual financial reporting, audit information, or management discussion of financial results. The document is a corporate announcement about sales orders and business outlook, which fits best under Capital/Financing Update (CAP) as it relates to business growth and potential revenue impact from new orders. It is not a report, transcript, or regulatory filing, but a business update press release.
2023-10-25 English
News release - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an exclusive distribution agreement between Groupe LSL Pharma and Fera Pharmaceuticals to address a drug shortage in the US market. It discusses the FDA's temporary authorization for importation and the supply arrangement but does not contain financial statements, earnings data, or regulatory filings. There is no indication of a report being attached or published, nor is it a certification or voting result. The content is clearly an announcement of a business agreement related to product distribution and supply chain, which fits best under Capital/Financing Update (CAP) as it relates to company financing and business operations updates rather than a financial report or regulatory filing.
2023-10-18 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing an exclusive distribution agreement between LSL Pharma Group and Fera Pharmaceuticals to address a drug shortage in U.S. hospitals. It includes details about the agreement, FDA temporary discretion, company descriptions, and forward-looking statements. There are no financial statements, regulatory filings, or detailed financial data. The document is a corporate announcement about a business agreement and not a financial report, regulatory filing, or other specific report types. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous corporate news, which corresponds to Regulatory Filings (RNS). The document length is 4567 characters, which is relatively short and typical for a press release. It does not announce voting results, management changes, or financial results, so other categories are not appropriate.
2023-10-18 English
News release - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Groupe LSL Pharma has engaged Paradox as its investor relations firm. It details the terms of the agreement, including fees and stock options, and provides background information about the company. There is no financial data, no report attached or referenced as being published, and no mention of regulatory filings or certifications. The content is an update on a capital/financing-related activity, specifically about investor relations services and stock options granted to the firm. This fits best under Capital/Financing Update (CAP). The document length is short (2737 characters), and it is clearly an announcement rather than a full report or regulatory filing.
2023-10-06 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that LSL Pharma Group has engaged Paradox as an investor relations services provider. It details the terms of the agreement, including fees and stock options, and provides background information about the company. There is no financial data, no regulatory filing references, no voting results, no management changes, no earnings or annual report content. The document is an announcement about a service engagement related to investor relations, which fits best under a general regulatory announcement category. It is not a report or detailed financial document, nor a certification or voting result. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-10-06 English
Material change report - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a Material Change Report pursuant to Canadian securities regulation (National Instrument 51-102), which includes a press release announcing the company's second quarter financial results for the period ended June 30, 2023. It contains detailed financial data such as revenues, gross profit, adjusted EBITDA, net loss, and shareholders' equity, along with management commentary and outlook. The presence of comprehensive financial statements and analysis for a quarterly period indicates this is an Interim / Quarterly Report. Additionally, the document announces the departure of the Chief Financial Officer, but the primary content is the financial results and discussion for the quarter. The document length (15,000 characters) and detailed financial data confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2023
2023-09-05 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.